Cambrian Genomics has raised a $10 million in a round with 127 participants. Some of them are Yammer co-founder Adam Pisoni; Draper Associates; and Cloudera founder Jeff Hammerbacher.
The company plans to use the new funds to keep working on its DNA-printing technology, and to start development of its incubator.
Glaxo Smith Kline is one of Cambrian’s clients, and Roche is next in line.Big pharma companies are asking Cambrian to print various types of DNA that can be used in the drug discovery and testing process. “We’re helping them make drugs,” Heinz said.
For example, Cambrian’s DNA can be used for producing small molecules or for making new screens to find small molecules.
Glaxo Smith Kline is one of Cambrian’s clients, and Roche is next in line. The company, called Personal Probiotics, uses Cambrian’s “Creature Creator” to print a special virus that kills off microbes in the vagina that cause yeast infections and other sexually transmitted diseases (STDs).
Cambrian also intends to print DNA for customers in the industrial chemical and agricultural industries. But perhaps the biggest initiative going on at Cambrian now is the development of its incubator, which supplies resources and work space to companies building products on its DNA-printing technology.
The company has filed for three DNA-printing patents, two of which are currently under review.